Filing Overview
Registrant: MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc. The Form 8-K was filed under Item 8.01, Other Events, with a report date of July 17, 2023 and a signature date of July 21, 2023.
Business Context and Reporting Period
The filing concerns Nasdaq listing compliance for MedTech Acquisition Corporation. It does not report quarterly or annual operating results and does not provide a financial reporting period.
Material Event
- On June 14, 2023, Nasdaq notified the company that its market value of listed securities did not satisfy Nasdaq Listing Rule 5550(b)(2), the market value of listed securities requirement.
- The company was given until December 11, 2023, to regain compliance.
- Nasdaq determined that the company’s market value of listed securities was at least $35 million for 15 consecutive business days from June 26 through July 14, 2023.
- On July 17, 2023, Nasdaq notified the company that it had regained compliance and that the matter was closed.
Financial Metrics, Liquidity, and Debt
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Guidance, Risks, and Unusual Items
No management guidance or operating outlook is provided. The principal disclosed risk was the company’s prior noncompliance with Nasdaq’s market value requirement; the filing states that this matter was resolved as of July 17, 2023.
Facts to Verify
- Confirm that the filing relates to MedTech Acquisition Corporation rather than Trisalus Life Sciences, Inc.
- Verify Nasdaq’s determination that the company maintained market value of listed securities of at least $35 million for the required 15 consecutive business days.
- Confirm the continued listing status of the company’s units, Class A common stock, and warrants on Nasdaq.